Skip to main content

Advertisement

Table 1 Very early subjects with an immediate treatment before seroconversion.

From: Timely HAART initiation may pave the way for a better viral control

ID Therapy therapy Elapsed days therapy At diagnosis* 4 weeks after** 8 weeks after**
    CD4 vRNA CD4 vRNA CD4 vRNA
Pz4 CBV, IDV 14 603 16000 800 < 50 792 6000
Pz34 CBV, EFZ 18 370 280000 647 640 815 < 50
Pz36 CBV, EFZ 15 402 14000   < 50 599 < 50
Pz38 CBV, EFZ 2 543 3500000   1600 770 220
Pz41 CBV, EFZ 12 568 1300000 1549 < 50 857 < 50
Pz42 CBV, EFZ 8 234   1083 2300 657 < 50
Pz47 CBV, IDV 4 753 8802 615 220 743 < 50
Pz51 CBV, EFZ 10 530 91972 655 < 50 810 < 50
Pz67 CBV, KAL 0 797 21675 884 98 932 < 50
Pz83 CBV, KAL 18 426 > 500000 770 2349 1524 1037
Pz113 CBV, KAL 3 261 65716 422 660 460 302
  1. Clinical information about the eleven patients selected at the Clinical Department of the National Institute for Infectious Disease "L. Spallanzani" in Rome. All subjects received HAART within six months from primary infection.
  2. CBV, Combivir (AZT Zidovudine plus 3TC Lamivudine); IDV, Indinavir; EFZ, Efavirenz; KAL, Kaletra (lopinavir/ritonavir). Days elapsed from diagnosis (enrollment) to initiation of HAART. *CD4 and CD8 are per microlitre of plasma, viremia is per millilitre of plasma. ** 4 weeks after treatment interruption.